Literature DB >> 15000422

Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.

Liping Zhang1, Stuart L Beal, Lewis B Sheinerz.   

Abstract

A model can be fit to joint PK/PD data (concentration and effect) either simultaneously or sequentially. The results of a companion paper suggested that when the data-analytic and true models agree, a particular sequential approach is computationally faster than the simultaneous one, yet produces hardly less precise PD parameter estimates, and for suitable designs, about as accurate PD standard error estimates. In this paper, we compare the performance of various methods for the case that the data-analytic model is misspecified. We illustrate these methods by applying them to a set of real data. Using NONMEM, population PK/PD observations were simulated under various study designs according to a one- or two-compartment PK model and direct Emax or sigmoid Emax model. A one-compartment PK model and Emax PD model were fit to the simulated observations by simultaneous and sequential methods. Predictive performance (interpolation and extrapolation) of PD and the type-I error rate of a likelihood ratio test are compared. The real data set consists of PK and (more frequent) PD observations after administration of the muscle relaxant vecuronium. When only the PK data-analytic model is misspecified, the simultaneous method has greater precision than the sequential methods. However a sequential method that uses a non-parametric PK model performs better than both other methods when PK model misspecification is severe. When the PD data-analytic model is misspecified, sequential and simultaneous methods perform similarly. The analysis of the real data shows that the PK fitted with the simultaneous method can be quite sensitive to PD model misspecification, yielding a possible diagnostic for this type of misspecification.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15000422     DOI: 10.1023/b:jopa.0000012999.36063.4e

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  5 in total

1.  Consequence of exercise on the cardiovascular effects of l-propranolol in spontaneously hypertensive rats.

Authors:  L Brynne; L K Paalzow; M O Karlsson
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

2.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

3.  Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system.

Authors:  D M Foster
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

4.  Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide.

Authors:  K E Fattinger; D Verotta; H C Porchet; A Munafo; J Y Le Cotonnec; L B Sheiner
Journal:  Am J Physiol       Date:  1996-10

5.  Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study.

Authors:  P M Wright; P Hart; M Lau; M L Sharma; L Gruenke; D M Fisher
Journal:  Anesthesiology       Date:  1994-07       Impact factor: 7.892

  5 in total
  36 in total

1.  Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Authors:  Radojka M Savic; France Mentré; Marc Lavielle
Journal:  AAPS J       Date:  2010-11-11       Impact factor: 4.009

2.  Predicting allopurinol response in patients with gout.

Authors:  Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

3.  Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.

Authors:  Dongyang Liu; Hoi-Kei Lon; Debra C Dubois; Richard R Almon; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-16       Impact factor: 2.745

4.  Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation.

Authors:  Satoshi Ueshima; Daiki Hira; Chiho Tomitsuka; Miki Nomura; Yuuma Kimura; Takuya Yamane; Yohei Tabuchi; Tomoya Ozawa; Hideki Itoh; Minoru Horie; Tomohiro Terada; Toshiya Katsura
Journal:  AAPS J       Date:  2019-06-24       Impact factor: 4.009

5.  Optimal design for multivariate response pharmacokinetic models.

Authors:  Ivelina Gueorguieva; Leon Aarons; Kayode Ogungbenro; Karin M Jorga; Trudy Rodgers; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-21       Impact factor: 2.745

6.  Combining MCMC with 'sequential' PKPD modelling.

Authors:  David Lunn; Nicky Best; David Spiegelhalter; Gordon Graham; Beat Neuenschwander
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-01-09       Impact factor: 2.745

7.  Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; Ahmed Abbas Suleiman; An Vermeulen; Jing Liu; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

8.  Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.

Authors:  Yasuhiro Tsuji; Nicholas H G Holford; Hidefumi Kasai; Chika Ogami; Young-A Heo; Yoshitsugu Higashi; Akiko Mizoguchi; Hideto To; Yoshihiro Yamamoto
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

9.  Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model.

Authors:  Karen B Schneck; Xin Zhang; Robert Bauer; Mats O Karlsson; Vikram P Sinha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-22       Impact factor: 2.745

10.  Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.

Authors:  Hesham Al-Sallami; Fiona Newall; Paul Monagle; Vera Ignjatovic; Noel Cranswick; Stephen Duffull
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.